AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ORPEA

AGM Information Jul 28, 2022

1578_iss_2022-07-28_59fe39a0-32c1-4b25-b420-61f391afeebb.pdf

AGM Information

Open in Viewer

Opens in native device viewer

2022 ANNUAL GENERAL MEETING

MAJOR CHANGES IN THE ORPEA BOARD OF DIRECTORS

SUMMARY OF VOTING RESULTS

FINANCIAL CALENDAR

Puteaux, 28 July 2022 (7:30 pm CEST)

Changes in the Board of Directors and its Committees

Today's ORPEA Combined Annual General Meeting approved major changes in the ORPEA Board of Directors, appointing Guillaume Pepy1 , Isabelle Calvez, John Glen and David Hale as independent directors, as well as Chief Executive Officer Laurent Guillot as a non-independent director.

In light of the expiring terms of office announced on 3 July 2022 and of these appointments, the ORPEA Board of Directors now comprises 14 directors and includes:

  • 11 independent directors (i.e. 92%, excluding directors representing employees), the Chief Executive Officer and 2 directors representing employees;
  • 6 women (i.e. 50%, excluding directors representing employees);
  • 4 nationalities (American, British, French and Irish).

The new Board of Directors also confirmed the appointment of Guillaume Pepy as Chairman of the Board of Directors.

The Appendix contains a table providing personal and professional information on the members of the new Board of Directors.

During its first meeting, held at the end of the Combined Annual General Meeting, the new Board of Directors decided to change the duties assigned to its Committees. This reaffirmed its commitment to

1 The Board of Directors considers, on the recommendation of the Appointments and Remuneration Committee, that Guillaume Pepy fulfils all the independence criteria of the AFEP-MEDEF Code and that, even beyond these criteria, his relationship with CPPIB, which had ended by the date of his appointment, is in no way likely to affect his independence. Guillaume Pepy's candidacy was selected in the context of the selection process for candidate directors, conducted by the Appointments and Remuneration Committee with the assistance of a leading headhunter. It was in no way proposed by CPPIB, which no longer has any links whatsoever with Guillaume Pepy. He was providing advice under a consultancy contract which ended on 5 July 2022 but was not linked to CPPIB by an employment contract or by a corporate mandate. Guillaume Pepy did not receive any remuneration linked, directly or indirectly, to ORPEA's performance and, more generally, he no longer receives his fixed remuneration as a consultant from CPPIB since his contract has ended. Finally, it is specified that neither he nor CPPIB have any business relationship with ORPEA.

transformation, with the goal of better fulfilling its care mission, as well as accompanying fragile people and rise up to the associated challenges.

The composition of these Committees, which is set out below, was established in accordance with the recommendations of the AFEP-MEDEF Code, relating in particular to the proportion of independent members and the independence of their Chairmen.

The Audit Committee, renamed Audit and Risk Committee, has had its responsibility expanded and more clearly defined, in particular regarding risk-related duties.

As of 28 July 2022, it comprises six members: Olivier Lecomte (Chairman), Corine de Bilbao, Isabelle Calvez, David Hale, John Glen and Peugeot Invest Assets (represented by Bertrand Finet).

The Appointments and Remuneration Committee will take on more duties relating to overseeing talent pools to ensure a succession plan for the Executive Committee and other key roles, as well as to developing the HR policy.

As of 28 July 2022, it comprises five members: Peugeot Invest Assets (represented by Bertrand Finet, Chairman), Corine de Bilbao, Pascale Richetta, Joy Verlé and Laurent Serris (director representing the employees).

Finally, the CSR and Innovation Committee has become the Ethics, Quality and CSR Committee. This reinforces the Board of Directors' work by ensuring that Ethics, Quality and CSR are at the heart of its mission and activity of the Group.

As of 28 July 2022, it comprises four members: Corine de Bilbao (Chair), Pascale Richetta, David Hale and Sophie Kalaidjian (director representing employees).

The Committees' duties are set out in the Internal Rules of the Board of Directors, as amended on 28 July 2022, which are available on ORPEA's website at the following address https://www.orpeacorp.com/en/2011-12-21-17-32-45/governance

Two new independent directors will join the new Board of Directors when they are released from their current obligations. The composition of the Committees will be adjusted accordingly.

Summary of voting results for other resolutions

During this Meeting, the required majority of Company shareholders approved the resolutions relating to:

  • the approval of the 2021 financial statements, the appropriation of net profit and the approval of a related-party agreement;
  • the appointment of Mazars S.A. and the re-appointment of Deloitte & Associés as Standing Statutory Auditors, and the non-renewal of BEAS's term of office as Alternate Statutory Auditor;
  • the remuneration components for 2021 (excluding those pertaining to Yves Le Masne), the remuneration policies for corporate officers for 2022 and Philippe Charrier's remuneration components for 2022;
  • the renewal of the Board of Directors' financial authorisations and delegations;

  • specific changes to the Articles of Association and other changes to the Articles of Association to ensure regulatory compliance;
  • powers for formalities.

In line with the Board of Directors' recommendation, the resolution relating to Yves Le Masne's remuneration components for 2021 was rejected. He will therefore receive no annual bonus payment for the 2021 financial year.

It is furthermore specified that Yves Le Masne will not receive any compensation related to the termination of his duties, as the 2022 remuneration policy for him has been approved, and that he has lost the benefit of the shares granted to him in 2020 and 2021 due to the end of his term of office on 30 January 2022.

During this Meeting, and in particular after Mirova requested the inclusion of an item to this effect on the agenda of the Combined Annual General Meeting, Laurent Guillot gave his overview of the situation and outlined the key priorities that have been identified to begin improving and transforming the Group.

The replay of this Annual General Meeting and the answers to written questions sent in by shareholders are available on ORPEA's website at the following address:https://www.orpea-corp.com/en/2011-12- 21-17-09-36/shareholder-meeting/19-shareholders-en/372-%20general-shareholder-meeting-at-july-28-2022.

Voting results will be published on the website on 29 July 2022.

Financial calendar

Press releases relating to ORPEA's half-year results for 2022 and to revenue for Q3 2022 will be published, respectively, on 28 September 2022 and on 8 November 2022 after market close.

Appendix

Personal information Experience Position on the Board
Age2 Gend
er
Nationality Number of
shares3
Number of
offices held
in listed
companies
Independence First date of
appointment
Term of office Length of
service on the
Board
Involvement in
Committees
(C=Chair
/M=Member)
Guillaume Pepy 64 M French - 1 Yes 28/07/2022 AGM 2026 - -
Laurent Guillot 53 M French 1 1 No 28/07/2022 AGM 2026 - -
Laure Baume 46 F French 928 1 Yes 14/12/2016 AGM 2024 6 -
Corine de Bilbao 55 F French 40 2 Yes 23/06/2020 AGM 2024 2 Ethics, Quality and
CSR Committee
(C)
Audit and Risk
Committee (M)
Appointments and
Remuneration
Committee (M)
Isabelle Calvez 57 F French - 1 Yes 28/07/2022 AGM 2026 - Audit and Risk
Committee (M)
Bernadette
Danet
Chevallier
63 F French 246 1 Yes 16/09/2014 AGM 2025 8 -
Peugeot Invest
Assets,
represented by
Bertrand Finet
56 M French 3,261,353 3 Yes 15/02/2012 AGM 2023 10 Appointments and
Remuneration
Committee (C)
Audit and Risk
Committee (M)
John Glen4 62 M British and
Irish
- 1 Yes 28/07/2022 AGM 2026 - Audit and Risk
Committee (M)
David Hale 54 M Franco
American
- 1 Yes 28/07/2022 AGM 2026 - Audit Committee
(M)
Ethics, Quality and
CSR Committee
(M)
Olivier Lecomte 56 M French 230 2 Yes 16/11/2020 AGM 2025 2 Audit and Risk
Committee (C)
Pascale Richetta 63 F French 10 1 Yes 23/06/2020 AGM 2024 2 Appointments and
Remuneration
Committee (M)
Ethics, Quality and
CSR Committee
(M)
Joy Verlé4 43 F Franco
British
1 2 Yes 27/04/2017 AGM 2023 5 Appointments and
Remuneration
Committee (M)
Sophie
Kalaidjian
(director
representing
the employees)
44 F French 20 1 No 15/01/2015 AGM 2024 7 Ethics, Quality and
CSR Committee
(M)
Laurent Serris
(director
representing
the employees)
52 M French - 1 No 15/12/2020 AGM 2023 2 Appointments and
Remuneration
Committee (M)

2At the time of publication of the 2022 Notice of Meeting Brochure.

3At the time of publication of the 2021 Universal Registration Document.

4Candidates proposed by CPPIB.

About ORPEA

ORPEA is a leading global player, expert in the care of all types of frailty. The Group operates in 22 countries and covers three core businesses: care for the elderly (nursing homes, assisted living, home care), post-acute and rehabilitation care and mental health care (specialized clinics). It has more than 71,000 employees and welcomes more than 255,000 patients and residents each year.

https://www.orpea-group.com/

ORPEA is listed on Euronext Paris (ISIN: FR0000184798) and is a member of the SBF 120, STOXX 600 Europe, MSCI Small Cap Europe and CAC Mid 60 indices.

ORPEA NewCap Image 7

Investor Relations Director Tel.: +33 (0)1 44 71 94 94 Tel.: +33 (0)6 78 37 27 60 [email protected] [email protected] [email protected]

Investor Relations Investor Relations Media Relations

Benoit Lesieur Dusan Oresansky Charlotte Le Barbier

Laurence Heilbronn Tel.: +33 (0)6 89 87 61 37 [email protected]

Talk to a Data Expert

Have a question? We'll get back to you promptly.